Rolipram
Autophagy inhibitor
Product Specifications
Background
Rolipram has been observed to selectively inhibit cAMP-phosphodiesterase (PDE4) by recruiting PDE4 into cytosolic aggregates that are not membrane-encapsulated. A down-stream effect of this observation is the inhibition of autophagy. Under normal conditions, autophagosomes are coated with the autophagic marker light chain 3 (LC3). LC3 binds directly to p62 protein, which shuttles protein to aggresomes, eventually leading to an autophagic event. In the absence of LC3, protein aggregates will not undergo autophagy, and will remain as cytosolic aggregates, as seen with the inhibition of PDE4 by Rolipram. It promotes axonal regeneration (4).
CAS Number
61413-54-5
Product Name Alternative
4- (3- (Cyclopentyloxy) -4-methoxyphenyl) pyrrolidin-2-one
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cancer | Autophagy | Neuroscience | Neurodegeneration | Neurogenesis
Purity
>98% (TLC) ; NMR (Conforms)
Weight
0.01
Format
White to off-white solid.
Solubility
Soluble to 75 mM in DMSO and to 75 mM in ethanol.
Molecular Formula
C16H21NO3
Molecular Weight
275.35
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Kato H., et al. (1995) Eur J Pharmacol. 272(1): 107-10.
2. Christian F., et al. (2010) Cell Signal. 22(10): 1576-96.
3. Houslay M.D., & Christian F. (2010) Autophagy. 6(8): 1198-200. 4. E Nikulina et al PNAS; 2004; 101, 8786
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUM2598-50 1x 50 µL
CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), 1mg/mL
Sign In for Pricing
View Details 
